ArticleEuropean journal of medical research2025
Research on the inhibitory effect of hydrogen gas on ovarian cancer and potential mechanisms.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is one of the most fatal malignancies in women worldwide; current treatment approaches still struggle to effectively control tumor progression. Therefore, it is imperative to explore novel and more effective therapeutic approaches. Hydrogen shows promise as a novel adjuvant therapy, offering new perspectives for ovarian cancer treatment. This study primarily investigates the effects of hydrogen on SKOV3 ovarian cancer cell line viability, apoptosis, migration, invasion, MDA, SOD levels, and key regulatory proteins through experiments including CCK-8, flow cytometry, scratch assay, Transwell assay, immunofluorescence, Western blot, and ELISA. HE staining, TUNEL, immunohistochemistry, immunofluorescence, Western blot, and ELISA were used to verify the antitumor effects of hydrogen in vivo. The results showed that hydrogen inhibited cell viability, migration, and invasion, promoted apoptosis, and induced G1/G2 phase arrest in SKOV3 cells. Additionally, hydrogen promoted ROS production, downregulated the expression of HIF-1α, NF-κB p65, and P-p65 proteins, decreased SOD levels, and increased MDA levels. The results of animal experiments showed that the tumor weight and volume in the hydrogen group were significantly smaller than those in the control group. At the same time, hydrogen promoted tumor cell apoptosis, reduced the levels of angiogenesis markers within the tumor, lowered the protein levels of HIF-1α and p65, increased MDA levels, and decreased SOD levels. Hydrogen provides a new approach for the treatment of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.